Publications by authors named "Robert Rifkin"

Claim this Profile
B
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Robert Rifkin

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.
Alfred L Garfall, Rahul Banerjee, Laurent Frenzel, Cyrus Khandanpour, Yi Lin, Robert Rifkin

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Karthik Ramasamy, Ravi Vij, David Kuter, David Cella, Brian G M Durie, Robert M Rifkin

Clin Lymphoma Myeloma Leuk· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective small-molecule agonist of G protein-gated inwardly-rectifying potassium channels reduces epileptiform activity in mouse models of tumor-associated and provoked seizures.
Robert A Rifkin, Xiaoping Wu, Brianna Pereira, Brian Ja Gill, Edward M Merricks

Neuropharmacology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect MM Registry.
Howard R Terebelo, James Omel, Lynne I Wagner, James W Hardin, Robert M Rifkin

Clin Lymphoma Myeloma Leuk· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
Sikander Ailawadhi, Hans C Lee, James Omel, Kathleen Toomey, James W Hardin, Robert M Rifkin

Blood Cancer J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect MM Registry.
Rafat Abonour, Hans C Lee, Robert Rifkin, Sikander Ailawadhi, James Omel

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Robert Rifkin

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Leslie Ballas, Sikander Ailawadhi, Mohit Narang, Cristina J Gasparetto, Hans C Lee, Robert M Rifkin

Pract Radiat Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?
Manwar Al-Naqqash, Gilberto Castañeda-Hernández, Shao-Chin Chiang, Fahad Ibnshamsah, Tomás Reinert, Robert M Rifkin

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter

Future Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Robert M Rifkin

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology Centers.
Joshua Richter, Stephen J Noga, Robert Rifkin

J Natl Compr Canc Netw· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
Michael A Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Robert M Rifkin

Clin Lymphoma Myeloma Leuk· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Hans C Lee, Karthik Ramasamy, Katja Weisel, Rafat Abonour, James W Hardin, Robert M Rifkin

Clin Lymphoma Myeloma Leuk· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Barry Paul, Michaela Liedtke, Jack Khouri, Robert Rifkin, Mitul D Gandhi

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke, Robert M Rifkin

Leuk Lymphoma· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Robert M Rifkin, Jeffrey Crawford, Reshma L Mahtani, David C Dale, Mohit Narang

Support Care Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Reshma L Mahtani, Rajesh Belani, Jeffrey Crawford, David Dale, Lucy DeCosta, Robert Rifkin

Support Care Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study.
Jeff P Sharman, Carol F Kirchhoff, Robert M Rifkin

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Cristina Gasparetto, Sundar Jagannath, Robert M Rifkin, Brian G M Durie, Mohit Narang

Clin Lymphoma Myeloma Leuk· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Faith Davies, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani

Ann Hematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Robert M Rifkin

Future Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect MM Registry.
Hans C Lee, Sikander Ailawadhi, Cristina J Gasparetto, Sundar Jagannath, Robert M Rifkin

Blood Cancer J· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis